Article

Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility.

Department of Hygienics, Gifu Pharmaceutical University, Gifu, 502, Japan.
Biochemical and Biophysical Research Communications (Impact Factor: 2.28). 08/2001; 285(1):118-28. DOI: 10.1006/bbrc.2001.5135
Source: PubMed

ABSTRACT Autocrine motility factor (AMF) is a type of tumor-secreted cytokine which primarily stimulates tumor cell motility via receptor-mediated signaling pathways, and is thought to be connected to tumor progression and metastasis. Using in vivo models, we showed that critical neovascularization responded to a biological amount of AMF. This angiogenic activity was fixed by specific inhibitors against AMF. AMF stimulated in vitro motility of human umbilical vein endothelial cells (HUVECs), inducing the expression of cell surface AMF receptor localizing a single predominant perinuclear pattern closely correlated with its motile ability. AMF also elicited the formation of tube-like structures mimicking angiogenesis when HUVECs were grown in three-dimensional type I collagen gels. We further immunohistochemically detected AMF receptors on the surrounding sites of newborn microvessels. These findings suggest that AMF is a possible tumor progressive angiogenic factor which may act in a paracrine manner for the endothelial cells in the clinical neoplasm, and it will be a new target for antiangiogenic treatment.

0 Bookmarks
 · 
52 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Autocrine motility factor (AMF) is a tumor-secreted cytokine and is abundant at tumor sites, where it may affect the process of tumor growth and metastasis. AMF is a multifunctional protein capable of affecting cell migration, invasion, proliferation, and survival, and possesses phosphoglucose isomerase activity and can catalyze the step in glycolysis and gluconeogenesis. Here, we review the role of AMF and tumor environment on malignant processes. The outcome of metastasis depends on multiple interactions between tumor cells and homeostatic mechanisms; therefore elucidation of the tumor/host interactions in the tumor microenvironment is essential in the development of new prevention and treatment strategies. Such knowledge might provide clues to develop new future therapeutic approaches for human cancers.
    08/2008: pages 11-25;
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Autocrine motility factor (AMF) is a multifunctional cytokine that promotes cellular adhesion, proliferation, motility, anti-apoptosis, and tissue repair. Direct nerve implantation (DNI) is considered to be effective in peripheral motor nerve injuries with disuse of the distal nerve; however, the repaired muscle function is not satisfactory. In our study, purified AMF was injected in reinnervated muscle after DNI with the intention of assessing if AMF, as a malignant tumor-related cytokine, could improve motor plate regeneration and neuromuscular function restoration. METHODS: Purified AMF, which was extracted from AMF-transfected myoblast-conditioned medium, was regularly injected into the rat gastrocnemius in an established rat gastrocnemius denervation and reinnervation model. The nerve conduction velocity (NCV) of the tibial nerve, peak-to-peak value (PPV), area under the curve (AUC) of the compound muscle action potential (CMAP) and the Tibial Functional Index (TFI) were measured at 8, 16 and 24 weeks after injection. The regenerated endplates in gastrocnemius were examined by histochemical staining. In another group, an AMF-free solution was injected as the control. RESULTS: After the AMF injection, the direct-nerve-implanted muscle function recovery was better in terms of both the nerve velocity and the quality. The endplates in the experimental group also had a quantitative advantage in restoration. After comparing the histochemical-stained tissues, no indications of tumorigenesis were detected. CONCLUSIONS: AMF had positive effects on neuromuscular reparation and need more detailed research to determine the signalling pathways and side effects of AMF.
    Acta Neurochirurgica 02/2013; · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumour angiogenesis is essential for cancer growth and metastasis. Many new pathways have been recognised in the last few years, including genes involved in embryonic development of the vasculature, e.g. the notch/delta, ephrin/eph and the HOX genes. Furthermore, vascular mimicry, intussusception and recruitment of circulating endothelial cells may contribute to tumour vessels, as well as endothelial proliferation. A close link has emerged between hypoxia and the regulation of angiogenesis, with many angiogenic factors involved in hypoxia in endothelial cells and cancer cells. Examples include vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), adrenomedullin, oxygen-regulated protein 150, tumour necrosis factor (TNF) alpha, endothelins. Conversely, anti-angiogenic molecules such as thrombospondin are downregulated. The main pathway regulating these responses seems to be via the hypoxia inducible factor I alpha and its modulation by proline hydroxylases. Many oncogenes amplify the effects of the hypoxia pathway, e.g. PTEN mutations. Thus, a plethora of targets is now available for therapy. Most tumours express many different pathways, but some key ones are emerging. VEGF seems to be a core factor for endothelial growth, and blockade of hypoxia signalling also inhibits angiogenesis. One of the difficulties in assessing response to therapy, if only new vessels are inhibited, is that only small amounts of regression may occur. However, clinical trials are now incorporating pharmacodynamic measurements such as vascular permeability and responses have been reported for a wide range of anti-angiogenic agents, in particular the VEGF pathway inhibitors. Marked synergy with conventional treatment modalities has been shown in preclinical models and this paradigm is being followed in clinical trial development. Second generation drugs are now entering phase III trials and are likely to enter routine practice.
    EJC Supplements 01/2003; 1(2):1-12. · 2.71 Impact Factor